About BachemGroup
BachemGroup is a publicly listed company based in Bubendorf (Switzerland) founded in 1971. Peptides and complex APIs are developed and manufactured by BachemGroup. The company has 2,210 employees. Its chief executive, as recorded, is Thomas Fruh. Its website bachem.com draws about 168 thousand monthly visits. BachemGroup offers products and services including Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides.
Company details
Bachem is a listed technology-based company focused on peptide chemistry. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom synthesis for research labs completes their service portfolio. It claims to have 40 years of experience in peptide research and know-how in peptide chemistry and organic synthesis. Bachems GMP manufacturing facilities are located in Switzerland and the United States and are approved by the FDA and local authorities. In addition, the company is also, involved in more than 200 cGMP projects targeting New Chemical Entities. It is headquartered in Switzerland with subsidiaries in Europe and the US.
- Annual Revenue$876.86 M (USD)14.84as on Dec 31, 2025
- Net Profit$187.7 M (USD)23.74as on Dec 31, 2025
- EBITDA$239.54 M (USD)8.37as on Dec 31, 2025
- Investors
- Employee Count2,210
Products & Services of BachemGroup
BachemGroup offers a comprehensive portfolio of products and services, including Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs.
Ready-to-deliver peptides for research and development purposes.
Tailored production of peptides for specific client needs.
Development and manufacturing of oligonucleotide new chemical entities.
Apps and channels of BachemGroup
its YouTube channel Bachem has 835 subscribers and 30 videos.
Videos from BachemGroup
The most watched videos on BachemGroup's YouTube channel, Bachem (835 subscribers). Click a video to play it here.
More on Bachem.
Funding Insights of BachemGroup
- Total Rounds 2
- Investors Count 1
All 2 funding rounds of BachemGroup with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | Grant | – | – | ||
| Jan 2014 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in BachemGroup
BachemGroup has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for BachemGroup
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BachemGroup
11 people are tracked at BachemGroup (5 in leadership, 6 in board & advisors); the tracked headcount is 2,210.
| Name | Role | Group |
|---|---|---|
Thomas Fruh | CEO | Leadership |
Christoph Schuhr | VP, Quality Assurance & Regulatory Affairs | Leadership |
Thomas Meier | CEO & COO | Leadership |
Anne-Kathrin Stoller | Chief Marketing Officer | Leadership |
Ann-Kristin Jenssen | VP, Quality Assurance - Bachem Americas, Inc. | Leadership |
Peter Grogg | Board of Directors | Board & advisors |
Nicole Grogg Hötzer | Board of Directors | Board & advisors |
Helma Wennemers | Board of Directors | Board & advisors |
Alex Fässler | Board of Directors | Board & advisors |
Kuno Sommer | Chairman | Board & advisors |
Steffen Lang | Member | Board & advisors |
Complete people profiles for BachemGroup
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BachemGroup
BachemGroup is a publicly listed company on the SIX with ticker symbol BANB in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Jun 2001
- Listed onSWX: BANB
- Listed entityBachem Holding AG Class B
- Exchange sectorHealth technology
- ISINCH1176493729
- Share price80.00 CHF (-0.44% on the day) · 2026-05-11
- Market capitalisation6,025,957,474.00 CHF
- Price to earnings40.3
- EPS (diluted, trailing year)1.98 CHF
- Dividend yield1.06%
- Volume (last session)50,813
- Analyst consensusBuy
Financials of BachemGroup
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 695.1M CHF | 148.8M CHF | 189.9M CHF |
| 2024 | 605.3M CHF | 120.2M CHF | 175.2M CHF |
| 2023 | 577.3M CHF | 111.9M CHF | 165.9M CHF |
| 2022 | 531.7M CHF | 100.7M CHF | 159.6M CHF |
| 2021 | 503.2M CHF | 114.7M CHF | 156.5M CHF |
Detailed financial statements for BachemGroup
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BachemGroup
4 dated milestones of BachemGroup across 44 years, from founding to its latest funding, stage changes and deals.
- Founded BachemGroup is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Funding Latest funding round, Grant,.
Web traffic of BachemGroup
The website of BachemGroup (bachem.com) receives about 167.9K visits a month and ranks #280,794 among all websites worldwide, #9,635 in Biotechnology and Pharmaceuticals.
- Monthly visits167.9K
▲ 12.3% vs previous month
- Unique visitors70.7K
per month
- Global rank#280,794
among all websites
- Category rank#9,635
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.0
- Average visit43 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with BachemGroup. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ibr-inc.com | 100% | 3K | #14,169,954 | View details | |
peptide.co.jp | peptide.co.jp | 85% | #2,432,317 | – | |
| ambiopharm.com | 85% | 15.1K | #1,550,315 | View details | |
| pharmaoffer.com | 85% | 161.5K | #176,907 | View details | |
rootsanalysis.com | rootsanalysis.com | 85% | #710,325 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for BachemGroup
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bachemgroup
Complete news archive for BachemGroup
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BachemGroup
BachemGroup was founded in 1971 and raised its 1st funding round 43 years after it was founded.
BachemGroup is headquartered in Bubendorf, Switzerland. It is registered at Bubendorf, Basel-landschaft, Switzerland.
Thomas Fruh is the CEO of BachemGroup, as recorded in our data.
BachemGroup has 2,210 employees.
Annual revenue of BachemGroup is $876.86M as on Dec 31, 2025.
Bachem is a listed technology-based company focused on peptide chemistry. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom synthesis for research labs completes their service portfolio. It claims to have 40 years of experience in peptide research and know-how in peptide chemistry and organic synthesis. Bachems GMP manufacturing facilities are located in Switzerland and the United States and are approved by the FDA and local authorities. In addition, the company is also, involved in more than 200 cGMP projects targeting New Chemical Entities. It is headquartered in Switzerland with subsidiaries in Europe and the US.
BachemGroup offers Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs.
Yes, BachemGroup is publicly traded on SIX under the ticker symbol BANB.
BachemGroup has 1 investor. Key investors include European Union.
The website of BachemGroup receives about 168 thousand visits a month and ranks #280,794 among all websites worldwide.